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Summary
Background As the HIV epidemic in sub-Saharan Africa matures, evidence about the age distribution of new HIV 
infections and how this distribution has changed over the epidemic is needed to guide HIV prevention. We aimed to 
assess trends in age-specific HIV incidence in six population-based cohort studies in eastern and southern Africa, 
reporting changes in mean age at infection, age distribution of new infections, and birth cohort cumulative incidence.
Methods We used a Bayesian model to reconstruct age-specific HIV incidence from repeated observations of 
individuals’ HIV serostatus and survival collected among population HIV cohorts in rural Malawi, South Africa, 
Tanzania, Uganda, and Zimbabwe, in a collaborative analysis of the ALPHA network. We modelled HIV incidence 
rates by age, time, and sex using smoothing splines functions. We estimated incidence trends separately by sex and 
study. We used estimated incidence and prevalence results for 2000–17, standardised to study population distribution, 
to estimate mean age at infection and proportion of new infections by age. We also estimated cumulative incidence 
(lifetime risk of infection) by birth cohort.
Findings Age-specific incidence declined at all ages, although the timing and pattern of decline varied by study. The 
mean age at infection was higher in men (cohort mean 27·8–34·6 years) than in women (24·8–29·6 years). Between 
2000 and 2017, the mean age at infection per cohort increased slightly: 0·5 to 2·8 years among men and –0·2 to 
2·5 years among women. Across studies, between 38% and 63% (cohort medians) of the infections in women were 
among those aged 15–24 years and between 30% and 63% of infections in men were in those aged 20–29 years. 
Lifetime risk of HIV declined for successive birth cohorts.
Interpretation HIV incidence declined in all age groups and shifted slightly to older ages. Disproportionate new HIV 
infections occur among women aged 15–24 years and men aged 20–29 years, supporting focused prevention in these 
groups. However, 40–60% of infections were outside these ages, emphasising the importance of providing appropriate 
HIV prevention to adults of all ages.
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Introduction
Eastern and southern Africa are disproportionately 
affected by HIV, with an estimated 54% of 38 million 
people living with HIV worldwide and 43% of new 
worldwide infections in 2019.1 The estimated annual 
number of new infections in this region decreased 
from 1·5 million in 1997 to 730 000 in 2019.2 However, 
this number still remains substantially higher than the 
UNAIDS 2020 target of 500 000 new infections among 
adults worldwide.1
Since the early years of the HIV epidemic, population-
based cohort studies have been a key source of information 
about HIV epidemiology and trends in eastern and 
southern Africa.3 The ALPHA network began in 2005 as 
a collaboration of independently conducted population-
based health and demographic surveillance systems in 
eastern and southern Africa that assess HIV status.3 
Four cohort studies in the ALPHA network—Kisumu 
(Kenya),4 Manicaland (Zimbabwe),5 Rakai (Uganda),6 and 
uMkhanyakude (South Africa)7—and eight studies collect-
ively8 have reported declines in the overall incidence of 
HIV in adults. Few studies, however, assessed changes 
in age-specific incidence in maturing HIV epidemics. 
A 2019 systematic review of data from ten countries in 
sub-Saharan Africa found that HIV incidence is decreasing 
in adolescent girls and young women (aged 15–24 years) 
in the general population, although the evidence to assess 
a trend was scarce.9
Combination HIV prevention interventions, including 
antiretroviral therapy (ART), medical male circumcision, 
condom use, and behaviour change, have been rolled out 
across eastern and southern Africa.1 HIV prevention 
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initiatives increasingly aim to prioritise age groups at 
which most HIV infections occur. Most prominently, 
the Determined, Resilient, Empowered, AIDS-free, 
Mentored, and Safe (DREAMS) partnership, which is 
supported by the USA’s President’s Emergency Plan 
For AIDS Relief (PEPFAR) and was established in 2015, 
is a large-scale intervention focused on adolescent girls 
and young women in 15 countries in eastern and 
southern Africa.10 Data about age-specific HIV incidence 
and its trends over the epidemic provide an evidence 
base for interventions, insight about how combined 
interven tions affect the age distribution of new in-
fections, and guidance to optimise future prevention 
efforts.
Most estimates of HIV incidence in population-based 
cohort studies rely solely on longitudinal observation of 
HIV seroconversion—ie, HIV-negative individuals who 
are prospectively followed up and re-tested for HIV. Given 
high levels of migration in and out of populations11,12 and 
of non-participation in HIV testing,13 the reliance on 
individuals with a minimum of two test results discards 
substantial information about previous HIV incidence 
among individuals who are observed as HIV-positive upon 
enumeration into the cohort, and could lead to biased 
estimates of incidence over time. To incorporate data 
from all participants, we used a Bayesian model to jointly 
reconstruct age-specific HIV incidence and mortality 
using population-based HIV testing data and vital status 
information.
We aimed to assess trends in age-specific incidence 
over time in population-based cohort studies in Malawi, 
South Africa, Tanzania, Uganda, and Zimbabwe, reporting 
changes in mean age at infection, proportion of new in-
fections in different age groups, and cumulative incidence 
in successive birth cohorts.
Methods
Data sources
The ALPHA network is comprised of ten ongoing 
population-based demographic surveillance studies across 
southern and eastern Africa that conduct HIV serosurveys.3 
Six of these studies have collected demographic and HIV 
data on individuals aged 15 years and older since at least 
the early 2000s and are included in this analysis: Karonga 
(Malawi), uMkhanyakude (South Africa), Kisesa (Tanzania), 
Masaka and Rakai (Uganda), and Manicaland (Zimbabwe).
Each study conducts demographic surveillance involving 
enumeration of all household residents, births, deaths, 
and migrations in geographically defined populations. 
This is usually done via household visits at regular 
intervals. HIV serosurveys are done at different frequencies 
for each study (between annually and about every 3 years) 
and have different testing protocols and participation rates. 
Details of data collection and serological testing in each 
study are described elsewhere.5,14–18
Participants from each of the included cohorts gave 
written informed consent to participate and for their data 
to be analysed by researchers within the organ isation 
collecting the data and by their collaborators.3,5,14–18 The 
conduct of each longitudinal study is regularly reviewed 
by the relevant local ethics committee and the appropriate 
approvals were obtained. The London School of Hygiene 
Research in context
Evidence before this study
We searched PubMed, MEDLINE, and grey literature for English 
studies published between database inception and 
Nov 15, 2019 using the search terms “HIV”, “AIDS”, “incidence”, 
“age-specific”, “age patterns”, “proportion”, and “new 
infections”. We selected articles that reported on age-specific 
HIV incidence and proportion of HIV infections by age in eastern 
and southern Africa. Our search showed that several studies 
have reported HIV incidence in broad age categories (10–15 year 
age groups), though many estimates cover a single time period. 
A 2019 systematic review found evidence that HIV incidence is 
decreasing in adolescent girls and young women in eastern and 
southern Africa, but there was scarce evidence to assess a trend 
over time. UNAIDS estimates the proportion of new HIV 
infections in eastern and southern Africa among 
15–24-year-olds to be 50% among women and 30% among 
men.
Added value of this study
Our analysis provides a detailed assessment of changes in age 
patterns of HIV incidence in six population-based cohort studies 
in eastern and southern Africa, using a Bayesian model that 
jointly estimates HIV incidence and mortality using serosurvey 
and vital status data. We found that age-specific incidence has 
decreased over time in these six studies. 38–63% of new 
infections among women were in 15–24-year-olds, and 
30–63% of new infections in men were in 20–29-year-olds. 
The mean age at infection has started to increase in some 
studies as incidence has lowered, though changes were slight 
(–0·2 to 2·8 years). Although lifetime incidence has declined in 
most studies and sexes, substantial burden remains among 
women in uMkhanyakude, South Africa.
Implications of all the available evidence
As the HIV epidemic has matured, the relative contribution of 
different ages to new HIV infections has changed, supporting 
the importance of continuing to update HIV prevention 
strategies to reflect the changing disease burden. Age-targeting 
interventions for HIV prevention to adolescent girls and young 
women aged 15–24 years, as in the PEPFAR-supported DREAMS 
partnership, is supported by their high burden of HIV incidence, 
but variability between studies suggests that this is too narrow 
of a target in settings where age-specific incidence is less 
concentrated.
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& Tropical Medicine’s ethics committee approved the 
pooled analysis of the secondary data.
Further details on the ALPHA network have been 
published previously.3
Model description
We used a Bayesian model to simultaneously reconstruct 
age-specific incidence and mortality by sex in each 
cohort. By jointly modelling HIV incidence and survival 
after seroconversion, we incorporated data from study 
participants who were HIV-positive at first study visit 
or participated in only one serosurvey. Modelling the 
distribution of survival by age at infection enables these 
data to inform the timing and age of HIV seroconversion. 
These additional data increase the precision of age-
specific incidence trends compared with typical cohort-
based estimates of HIV incidence, which use only 
observations from participants with a HIV-negative test 
at baseline and a follow-up test.19
We jointly fit the model to individual records from 
demographic surveillance (whether an individual is living 
in the study area and, if yes, whether they are alive) and 
serosurveillance (HIV status if available). The model was 
specified by three hazard functions across time and age: 
We modelled HIV incidence hazard as a generalised 
additive model with an interaction between time and 
age,20 logλ(t,a)=f(t) + f(a) + f(t,a), where f(t) and f(a) specify 
average time and age pattern for incidence and the 
interaction f(t,a) allows for changes in the incidence 
age pattern over time. We modelled non-HIV mortal-
ity additively with average time and age patterns,21 
log μ(t,a)=g(t) + g(a). Each of the terms of the generalised 
additive models were represented by penalised B-splines 
(p-splines) with knots every 5 years in age and time.22 The 
p-splines used are flexibly modelled splines that penalise 
first-order differences between adjacent coefficients to 
smooth between terms.
We modelled HIV survival by age at infection with 
a Weibull hazard function (ω(a – u,u)) based on age 
at infection a–u and time since infection u.23 HIV 
mortality hazard is modified by the ratio hART(t) in the 
ART era (table), such that in pre-ART era, hART(t)=1, 
and in the ART era, hART(t) is estimated from the data 
on the basis of observed declines in the mortality of 
people living with HIV after ART became available. 
Diffuse prior distributions were specified for all spline 
co efficients and the variance on differences in spline co-
efficients; smoothness penalties were shared for men 
and women within each study, but spline coefficients 
were a priori conditionally independent between sexes.
The data for each individual consist of the dates first 
observed in demographic surveillance and last observed 
alive in the study or date of death, and a collection of HIV 
status observations from rounds of HIV serosurveys. 
HIV status observations defined an interval in which 
each individual could have seroconverted. For a specific 
seroconversion date in this interval, the likelihood for an 
observed individual is the probability of surviving to time 
last observed or died, conditional on having survived HIV-
free to time of seroconversion and survived with HIV from 
seroconversion to time last observed or died. The model 
integrates over all possible seroconversion times from last 
HIV-negative observation to first HIV-positive observation. 
There are four cases of sero conversion intervals: (1) those 
HIV-positive at first observation (left-censored), for whom 
the seroconversion interval starts at age 10 years (start 
of the model); (2) those HIV-negative at last observation 
(right-censored) could seroconvert anytime from time 
last observed HIV-negative until last observation or 
death in demographic surveillance; (3) those with a HIV-
negative and HIV-positive test (interval-censored) who 
sero converted between these two tests; and (4) those with 
no HIV testing data who could have seroconverted anytime 
between first observation to last observation or death. 
By considering all four cases described, we used all HIV 
serostatus information to inform HIV incidence estimates, 
rather than exclusively using the cohort of seroconverters.
We reconstructed HIV incidence from the introduction 
of HIV in each study population, but since demographic 
surveillance and HIV serosurveillance only began 
several years into the epidemic, we added auxiliary 
information to specify an early prevalence of 0% before 
the HIV epidemic started in each study.24 For this 
auxiliary information, we inserted a hypothetical cross-
sectional HIV serosurvey of 451 adults, aged 15–60 years 
by 0·1 of a year, with all HIV-negative individuals (year 
in appendix p 17).
For computation, the model and data were discretised 
to 0·2 year time-steps. We estimated the model using 
Hamiltonian Monte Carlo, No-U-Turn samplers in the 











Karonga (Malawi) 2002 43 056 271 608 4 6% 2005
Kisesa (Tanzania) 1994 66 204 297 548 8 6% 2005
Manicaland (Zimbabwe) 1998 29 434 141 116 6 18% 2005
Masaka (Uganda) 1989 30 649 181 234 25 7% 2004
Rakai (Uganda) 1994 61 887 289 135 17 14% 2004
uMkhanyakude 
(South Africa)
2000 102 936 690 116 14 25% 2005
Data are for the survival cohort, except HIV-positive test data (ever collected). Additional details are given in the 
appendix (pp 14–19). ART=antiretroviral therapy. 
Table: Data availability and model inputs for individuals aged ≥15 years, ALPHA network 1989–2017
λ(t, a): HIV incidence rate at time t and age a;
ρ(t, a, u)=ω(a–u, u)⋅hART(t): HIV-related death rate for
time t, age a, and duration of infection u;
μ(t, a): natural (non-HIV) mortality rate at time t and
age a
See Online for appendix
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Figure 1: Age-specific HIV 
incidence modelled 
estimates in six ALPHA 
network studies by age 
group (A) and by year (B)
(A) Rakai does not include a 
line for age 45–54 years 
because the cohort has largely 
not done HIV tests in 
individuals older than 49 years. 
(B) Karonga, Manicaland, and 
uMkhanyakude do not include 
results for 2000 and 2015, 
2015, and 2000, respectively, 
due to different start and end 
dates of HIV testing rounds. 
More details on serosurvey 
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four independent chains for 500 iterations, and com-
bined the latter 250 iterations of chains to calculate 
summary statistics of the posterior distribution.
Additional model details are given in the appendix 
(pp 3–14).
Statistical analysis
We estimated (1) age-specific incidence over time, 
(2) mean age at infection over time, (3) proportion 
of infections occurring within 5-year age groups, 
(4) narrowest age ranges that capture 25%, 50%, and 
75% of new infections, and (5) cumulative incidence 
(lifetime risk of infection) by birth cohort.
For analyses of age distributions of new HIV infections, 
we applied modelled age-specific incidence rates and 
prevalence to the age structure of the resident population 
in the study areas enumerated through demographic 
surveillance (regardless of whether they participated in 
HIV serosurveys), with no smoothing between surveil-
lance. Since Manicaland does not conduct continuous 
demographic surveillance, we standardised to the national 
population.26 Modelled HIV prevalence was applied to 
produce estimates of the population susceptible by time 
and age, to which we applied incidence hazards to calcu -
late new infections by age. Mean age at infection was 
weighted by the population susceptible in each age group 
wt,a at each time t:
Cumulative incidence by birth cohort was calculated 
by cumulating the hazard across age-specific and 
time-specific incidence estimates by birth year: 
1 – exp(–t·Σ(t,a) λ(t,a)).
We projected future cumulative incidence by birth 
cohort under two assumptions: (1) future age-specific 
incidence rates remain constant at the most recent 
estimated levels (2012 for Karonga and Manicaland, 
2017 for uMkhanyakude, Rakai, Masaka, and Kisesa), 
and (2) age-specific HIV incidence rates continue to 
decline at the same study-specific and sex-specific rate 
estimated for the past 5 years among ages 15–54 years. 
Sex differences in the rate of incidence decline are 
reduced from the end of the data period, converging in 
2022 after which the rate of decline is assumed to be the 
same in both sexes (appendix pp 31–32).
For each outcome, we present results for 2000–17 or 
end of the most recent HIV serosurveillance in each 
study (2012 in Karonga and Manicaland) for individuals 
aged 15–54 years due to limited serosurveillance in those 
younger than 15 years and older than 54 years. Results 
represent the median of 1000 posterior samples, with 
95% credible intervals (95% CrIs) representing the 2·5th 
and 97·5th percentiles of these distributions. We used 
R statistical software (version 3.6) to analyse modelled 
outputs. Owing to substantial variability in the magnitude 
of HIV epidemics in the different studies, plotted results 
are presented side-by-side with different vertical axis 
ranges.
Analyses assessing sensitivity to assumptions about 
the type of HIV incidence hazard smoothing term, the 
population standardised to, and comparisons of modelled 
outputs to direct estimates from seroconverter cohorts 
are shown in the appendix (pp 34–53).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
Age-specific incidence decreased over time across most 
age groups in these studies, though decreases were 
observed at different times (figure 1A). In 2000 and 2005, 
HIV incidence generally peaked between ages 20–24 years 
for women and 25–29 years for men (figure 1B). Over 
time, age-specific incidence flattened in Karonga, Kisesa, 
Manicaland, and Masaka. In Rakai and uMkhanyakude, 
the peaked incidence age pattern did not change. Recent 
incidence declines among women in uMkhanyakude 
were greatest below age 30 years. HIV prevalence trends 
by age group are shown in the appendix (p 29). 
The mean age at infection was higher in men than 
women in all studies, and the difference between the sexes 
remained similar over time (figure 2). In the most recent 
estimate (2012 for Karonga and Manicaland, 2017 for 
elsewhere), mean age at infection among men was 
27·8 years (95% CrI 26·7–29·1) in uMkhanyakude, 29·2 
(27·5–31·0) in Rakai, 31·1 (29·6–33·0) in Manicaland, 
( )Σaλ(t,a)·a·wt,aΣaλ(t,a)·wt,a
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Karonga: women (Malawi) Karonga: men (Malawi) Kisesa: women (Tanzania) Kisesa: men (Tanzania)
Masaka: women (Uganda) Masaka: men (Uganda) Rakai: women (Uganda) Rakai: men (Uganda)
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32·1 (30·4–34·4) in Karonga, 32·2 (29·5–35·6) in Masaka, 
and 34·6 (31·3–37·5) in Kisesa. Among women, most 
recent mean age at infection was 24·8 years (95% CrI 
24·1–25·7) in uMkhanyakude, 25·5 (24·2–27·2) in Rakai, 
27·3 (24·9–31·0) in Masaka, 27·7 (26·6–29·0) in 
Manicaland, 29·0 (27·3–31·1) in Karonga, and 29·6 
(26·7–33·3) in Kisesa. The mean age at infection increased 
slightly from 2000 to most recent estimate in Kisesa 
(2·8 years in men, 2·5 in women), Masaka (1·8 years in 
men, 1·5 in women), Manicaland (1·5 years in men, 1·6 in 
women), Karonga (1·2 years in men, 1·2 in women), and 
Rakai men (0·7 years); women in Rakai showed little 
change (–0·2 years). Mean age at infection decreased 
between 2000 and 2017 in uMkhanyakude (–2·8 years in 
men, –2·2 in women), although the mean age at infection 
increased slightly between 2013 and 2017 (0·5 years in 
men, 0·3 in women).
The proportions of new infections occurring in each 
5-year age group was relatively stable over time and broadly 
similar across studies (figure 3). In all studies, for those 
aged 15–19 years, a higher proportion of infections occur 
among women (14–29%) than men (5–11%), whereas men 
have a greater proportion of infections among those aged 
25–34 years (23–40% among women and 30–48% among 
men). In Kisesa, age at infection was more evenly 
distributed across ages than in other studies.
38–63% (cohort medians) of the infections in women 
were among those aged 15–24 years (figure 3). This value 
was above 50% in the most recent year for three of 
six studies: uMkhanyakude (63%, 95% CrI 59–67), Rakai 
(60%, 52–69), and Masaka (53%, 37–66). In the other 
three studies, this proportion was below 50%: Karonga 
(38%, 28–46), Kisesa (41%, 27–55), and Manicaland (42%, 
35–49). Among men in the most recent year, while 
15–24-year-olds represented 19–39% of infections in 
men, men aged 20–29 years represented more than 
50% of infections in uMkhanyakude (63%, 54–69) and 
Rakai (52%, 43–61), and less than 50% in Manicaland 
(44%, 32–54), Karonga (40%, 30–49), Masaka (36%, 
25–47), and Kisesa (30%, 18–43). The uncertainty ranges 
for these estimates show substantial uncertainty around 
the proportion of infections attributable to each age 
group. Uncertainty was largest in the youngest age group 
and in smaller studies.
Across studies, the width of the age range within which 
75% of new infections occurred in the most recent year 
was 13·2–22·2 years for women and 13·2–24·6 years for 
men (figure 4). For women in Rakai and uMkhanyakude, 
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the narrowest band to capture 75% of infections lies, 
in most years, between ages 15 years and 30 years, the 
most recent estimate is 15·0–29·2 years in Rakai and 
15·2–28·4 years in uMkhanyakude. Among women in 
Karonga, Kisesa, Manicaland, and Masaka, this 75% band 
extends slightly older at 15–35 years, with some changes 
over time in Manicaland and Masaka as infections in 
women have shifted to older ages. Most recent estimates 
are 15·0–34·8 years in Karonga, 15·0–37·2 years in Kisesa, 
17·4–33·8 years in Manicaland, and 15·0–34·2 years in 
Masaka.
Among men in the most recent estimates, the narrowest 
band to capture 75% of infections is in ages 20–35 years 
in Rakai and uMkhanyakude (most recent estimates are 
18·4–35·8 years in Rakai and 19·6–32·8 years in 
uMkhanyakude), closer to ages 20–40 years in Karonga 
and Manicaland (most recent estimates are 21·6–40·8 years 
in Karonga and 21·0–38·6 years in Manicaland), and 
some what wider in Kisesa and Masaka (most recent esti-
mates are 21·2–45·2 years in Kisesa and 17·8–42·4 years 
in Masaka; figure 4).
The lifetime risk of HIV infection, measured by 
cumulative incidence of HIV infection between ages 
15 years and 49 years, has declined for more recent 
birth cohorts in all studies; however, declines in 
women in uMkhanyakude occur later than for all 
other studies and sexes (figure 5). For the birth cohort 
turning 50 years old in 2020, the percentage of 
women who were infected with HIV (either deceased 
or surviving) was 28% (95% CrI 25–32) in Kisesa, 
34% (31–38) in Karonga, 40% (32–51) in Rakai, 
45% (36–48) in Masaka, 53% (51–56) in Manicaland, 
and 70% (67–72) in uMkhanyakude. In uMkhanyakude, 
we projected that cumulative incidence will peak for 
the cohort turning 50 years old in 2029 at 79% (77–81). 
For men, the cumulative incidence for the cohort 
turning 50 years old in 2020 was similar to women in 
the same population—ranging from 24% (21–28) in 
Kisesa to 53% (49–56) in Manicaland and 69% (66–71) 
in uMkhanyakude. By contrast, HIV prevalence at the 
most recent estimate among 45–54 year olds in each 
study was lower in both sexes, at 14–26% in Kisesa, 
Karonga, Masaka, and Manicaland and 45–48% in 
uMkhanyakude (appendix p 29).
If incidence of HIV were to remain constant at 2017 
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Figure 4: Narrowest age bands accounting for 25%, 50%, and 75% of new HIV infections in six ALPHA network studies
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Figure 5: Cumulative 
incidence of HIV at ages 25, 
35, and 50 years by birth 
cohort in six ALPHA network 
studies by sex
Data are cumulative incidence 
of HIV at the specified ages, 
which were projected 
assuming current period 
age-specific incidence and 
assuming a continuation of 
the relative reduction seen in 
the past 5 years. 
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will have cumulative incidence from 11% (95% CrI 7–17) 
in Karonga to 24% (19–29) in Manicaland and 63% (51–73) 
in uMkhanyakude, representing relative reductions of 
10–70% from 2020 levels. Notably, among women in 
uMkhanyakude, cumulative incidence at age 20 would be 
13·5% when assuming constant incidence at 2017 levels. 
For men, birth cohort cumulative incidence at age 50 in 
2050 will range from 11% (5–18) in Karonga to 18% (12–26) 
in Manicaland and 27% (14–44) in uMkhanyakude, 
a reduction of 36–65% since 2020.
If incidence continues to decline at the rate observed 
in the past 5 years in both sexes, the cohort turning 
50 years old in 2050 will have a median risk of infection 
of less than 12% in all studies except uMkhanyakude, 
where the projected cumulative incidence will reduce to 
34% (95% CrI 27–43) for women and 7% (4–13) for men.
Discussion
Our modelling analysis showed that age-specific incidence 
of HIV has declined over time in all six population-based 
cohort studies, although the magnitude and timing of this 
decline varied across studies and between sexes. In studies 
with lower current epidemic levels and earlier declines 
in incidence—Karonga (Malawi), Kisesa (Tanzania), 
Manicaland (Zimbabwe), and Masaka (Uganda)—the age 
pattern of incidence flattened across ages over time and 
the mean age at infection was slightly older than in other 
studies and increased since 2000. In Rakai (Uganda) 
and uMkhanyakude (South Africa), where  incidence until 
2008 and 2012, respectively, was somewhat higher but has 
declined rapidly, the distribution of age at infection was 
younger and the historical peak of age-specific incidence 
was maintained. Early analyses of the most recent HIV 
serosurvey in Rakai reported extremely low incidence in 
young women (0·21 per 100 person-years among women 
aged 15–24 years), suggesting that Rakai might also be 
shifting into the first grouping of studies.27 
In the past 5 years, HIV prevention strategies have 
increasingly focused on prioritising HIV prevention to 
age groups at the highest risk of HIV. The PEPFAR 
DREAMS partnership and South Africa’s She Conquers 
initiative have made large investments in HIV prevention 
and risk reduction focused on adolescent girls and young 
women.10 Some stakeholders have raised concerns that 
these approaches neglect women aged 25–34 years with 
high HIV incidence rates, and they encourage the 
provision of HIV prevention for women of all ages.28 
For men, questions persist about the short-term and 
long-term value of promoting voluntary medical male 
circumcision among different age groups.29
Our findings underscore the importance of providing 
effective HIV prevention for adults at risk of HIV across 
all ages. While there was some variation across study 
populations in the age distribution of new infections, 
38–63% of current new infections among women are 
among those aged 15–24 years, and 14–29% among 
those aged 15–19 years. These data highlight the 
efficiency of focusing large-scale HIV primary prevention 
on adolescent girls and young women. However, such 
strategies in isolation would exclude roughly 40–60% of 
infections occurring among women older than 25 years. 
Other research has shown that women who are 
widowed or divorced, in sero discordant partnerships, 
engaged in high-risk activity (such as sex work or 
transactional sex), or living in locations with high HIV 
prevalence and unsuppressed viral load, are at increased 
risk for acquiring HIV,1 which might focus optimal 
HIV prevention provision for these ages.
Our estimates of the age distribution of new infections 
from population-based cohort studies were broadly con-
sistent with UNAIDS estimates for eastern and southern 
Africa, which have guided age-targeted intervention 
strategies. UNAIDS reported that, in 2019, 50% of new 
infections in adult women and 30% in adult men were 
among those aged 15–24 years,1 compared with 38–63% for 
women aged 15–24 years and 19–39% for men aged 
15–24 years across our study populations.
The mean age at infection increased slightly in most 
studies by 0·7 to 2·8 years since 2000, which might reflect 
both natural HIV epidemic dynamics and interventions 
focused on young adults. In uMkhanyakude, the population 
with the largest epidemic and in which incidence peaked 
and declined most recently of the populations studied here, 
we estimated that the mean age at infection decreased 
throughout the 2000s but increased from 2013, later than 
other study populations. These findings are consistent with 
South Africa’s later HIV epidemic, with previous modelling 
work showing that mean age at infection would decrease 
through the 2000s due to saturation of infections among 
older ages.30 The older mean age at infection in populations 
with lower overall incidence is consistent with foundational 
findings from infectious disease dynamics; for example, 
the relationship between force of infection and age at 
infection for vaccine preventable childhood infections.31 
Although simple formulaic relationships do not directly 
apply to highly structured age patterns of HIV risk, 
heterogeneity in mixing, and complex interventions, the 
disease dynamics perspective could help to guide optimal 
interventions across epidemic settings into the future.
Although HIV prevalence in adults aged 45–54 years 
peaked at 14–26% in most studies and at 45–48% in 
uMkhanyakude, the cumulative effect of the epidemic on 
birth cohorts passing through adulthood during the late 
1990s and early 2000s was much more severe. 28–53% of 
the birth cohorts turning 50 years old in 2020, excluding 
uMkhanyakude, ultimately became infected with HIV. In 
uMkhanyakude, up to 70% (95% CrI 67–72) of women 
were infected in the most affected cohorts to date, which 
is anticipated to increase to 79% (77–81) for women 
turning 50 years old in 2029. Although HIV point 
prevalence is lower for men than for women, the peak 
cumulative proportion infected was similar between 
sexes. However, we project that, in uMkhanyakude, the 
female:male ratio in cumulative incidence at 50 years 
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old will increase over time. Lifetime risk of infection 
decreased substantially for more recent birth cohorts. In 
the absence of a reversal of these trends, our findings 
support projections that the number of young people 
living with HIV will decrease over time.32 However, 
further reductions in incidence are needed to control 
HIV transmission, particularly in uMkhanyakude where 
estimated age-specific incidence rates still resulted in 
13·5% cumulative incidence by age 20 among adolescent 
girls and young women when assuming constant 
incidence at 2017 levels.
Our study has some limitations. First, the geo-
graphically localised nature of these population-based 
cohort studies, which are mostly rural populations under 
surveillance for long periods that were initially selected as 
highly HIV-affected populations, limits the generali-
sability of our findings. However, the consistency of age-
specific incidence dynamics seen across these populations 
gives us some confidence that our conclusions are likely 
to be similar to other southern and eastern African 
populations. Health and demographic surveillance in 
urban populations in sub-Saharan Africa are being 
expanded33 and will provide vital resources for under-
standing incidence patterns in urban areas. Second, the 
six studies we included did not systematically include 
HIV testing for individuals younger than 15 years, so 
trends in younger ages were not characterised here. 
Third, our cumulative inci dence projections by birth 
cohort reflect two simplified assump tions. Mechanistic 
modelling could provide improved projections of future 
incidence trends. Finally, our analyses only assess HIV 
acquisition, instead of risk of transmission, and can thus 
only provide half of the information to guide interventions 
for HIV prevention.  Phylogenetic studies have helped to 
inform who is transmitting the virus.34
Decreases in age-specific incidence across almost all 
ages suggest that the HIV epidemic in these study 
populations has contracted substantially. Successive 
birth cohorts entering adulthood in the 2000s have 
experienced substantially lowered lifetime probability 
of HIV infection. Our findings emphasise the import-
ance of providing appropriate HIV prevention to adults 
across all age ranges and continuing to adapt inter-
ventions to different contexts as infections shift over 
time.
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